Literature DB >> 16317705

Conjugated bile acids promote ERK1/2 and AKT activation via a pertussis toxin-sensitive mechanism in murine and human hepatocytes.

Paul Dent1, Youwen Fang, Seema Gupta, Elaine Studer, Clint Mitchell, Sarah Spiegel, Philip B Hylemon.   

Abstract

Several studies have argued that G-protein-coupled receptors (GPCR) have the capacity to promote activation of receptor tyrosine kinases. The current studies were performed to examine the regulation of the extracellular regulated kinase (ERK)1/2 and AKT pathways by conjugated and unconjugated bile acids in primary hepatocytes. Deoxycholic acid (DCA), chenodeoxycholic acid (CDCA), taurodeoxycholic acid (TDCA), glycodeoxycholic acid (GDCA), taurochenodeoxycholic acid (TCDCA), glycochenodeoxycholic acid (GCDCA), taurocholic acid (TCA), glycocholic acid (GCA), and tauroursodeoxycholic acid (TUDCA) all activated ERK1/2 in primary rat hepatocytes that was abolished by inhibition of ERBB1, and significantly reduced by ROS quenching agents. Bile acid-induced AKT activation was blunted by preventing ERBB1 activation and ROS generation. Treatment of rat hepatocytes with pertussis toxin (PTX) did not alter ERK1/2 and AKT activation induced by DCA or CDCA but abolished pathway activations by conjugated bile acids. Similar data to those with PTX were obtained when a dominant negative form of G(i1alpha) was overexpressed. Treatment of rat hepatocytes with TDCA and TCA promoted guanosine triphosphate (GTP) loading of G(i1alpha), G(i2alpha), and G(i3alpha) in vitro. Treatment of rat hepatocytes with PTX abolished TDCA-induced tyrosine phosphorylation of ERBB1. Similar findings to those in rat hepatocytes were also obtained in primary mouse and human hepatocytes, but not in established rodent or human hepatoma cell lines. In conclusion, collectively our findings demonstrate that unconjugated bile acids activate hepatocyte receptor tyrosine kinases and intracellular signaling pathways in a ROS-dependent manner. In contrast, conjugated bile acids primarily activate receptor tyrosine kinases and intracellular signaling pathways in a GPCR (G(ialpha))-dependent and ROS-dependent manner.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16317705     DOI: 10.1002/hep.20942

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  50 in total

1.  Lysophosphatidic acid activates lipogenic pathways and de novo lipid synthesis in ovarian cancer cells.

Authors:  Abir Mukherjee; Jinhua Wu; Suzanne Barbour; Xianjun Fang
Journal:  J Biol Chem       Date:  2012-06-03       Impact factor: 5.157

2.  Activation of the farnesoid X receptor induces hepatic expression and secretion of fibroblast growth factor 21.

Authors:  Holly A Cyphert; Xuemei Ge; Alison B Kohan; Lisa M Salati; Yanqiao Zhang; F Bradley Hillgartner
Journal:  J Biol Chem       Date:  2012-06-01       Impact factor: 5.157

3.  Conjugated bile acids activate the sphingosine-1-phosphate receptor 2 in primary rodent hepatocytes.

Authors:  Elaine Studer; Xiqiao Zhou; Renping Zhao; Yun Wang; Kazuaki Takabe; Masayuki Nagahashi; William M Pandak; Paul Dent; Sarah Spiegel; Ruihua Shi; Weiren Xu; Xuyuan Liu; Pat Bohdan; Luyong Zhang; Huiping Zhou; Phillip B Hylemon
Journal:  Hepatology       Date:  2011-11-30       Impact factor: 17.425

Review 4.  Role of nuclear receptor SHP in metabolism and cancer.

Authors:  Yuxia Zhang; Curt H Hagedorn; Li Wang
Journal:  Biochim Biophys Acta       Date:  2010-10-20

5.  A novel ASBT inhibitor, IMB17-15, repressed nonalcoholic fatty liver disease development in high-fat diet-fed Syrian golden hamsters.

Authors:  Mao-Xu Ge; Wei-Xiao Niu; Jin-Feng Ren; Shi-Ying Cai; Dong-Ke Yu; Hong-Tao Liu; Na Zhang; Yi-Xuan Zhang; Yu-Cheng Wang; Rong-Guang Shao; Ju-Xian Wang; Hong-Wei He
Journal:  Acta Pharmacol Sin       Date:  2018-12-20       Impact factor: 6.150

6.  How we have learned about the complexity of physiology, pathobiology and pharmacology of bile acids and biliary secretion.

Authors:  Jose J G Marin
Journal:  World J Gastroenterol       Date:  2008-10-07       Impact factor: 5.742

7.  Farnesoid X receptor antagonizes JNK signaling pathway in liver carcinogenesis by activating SOD3.

Authors:  Yan-Dong Wang; Wei-Dong Chen; Cunbao Li; Cong Guo; Yanyan Li; Hui Qi; Hailing Shen; Jing Kong; Xuecheng Long; Frank Yuan; Xichun Wang; Wendong Huang
Journal:  Mol Endocrinol       Date:  2014-12-12

8.  Bile Acid Receptors and Liver Cancer.

Authors:  Xichun Wang; Xianghui Fu; Carl Van Ness; Zhipeng Meng; Xiaoxiao Ma; Wendong Huang
Journal:  Curr Pathobiol Rep       Date:  2012-12-21

9.  Farnesoid X receptor-Acting through bile acids to treat metabolic disorders.

Authors:  Yanqiao Zhang
Journal:  Drugs Future       Date:  2010-08-01       Impact factor: 0.148

10.  Tauroursodeoxycholic Acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women.

Authors:  Marleen Kars; Ling Yang; Margaret F Gregor; B Selma Mohammed; Terri A Pietka; Brian N Finck; Bruce W Patterson; Jay D Horton; Bettina Mittendorfer; Gökhan S Hotamisligil; Samuel Klein
Journal:  Diabetes       Date:  2010-06-03       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.